Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 9855531.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Spasticity is a disabling symptom of MS that is enhanced during interferon beta-lb (IFNbeta-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNbeta-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNbeta-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.
Medical subject headings
- Adjuvants, Immunologic
- Immunotherapy
- Interferon-beta
- Multiple Sclerosis
- Muscle Spasticity